28 search results for: pediatric

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in <b>Pediatric</b> Severe Asthma?
expert video

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

Pulmonology
In this ADVENT symposium at the 2024 European Respiratory Society conference, Drs. Sharon Dell and Leonard Bacharier discuss the potential domains of on therapy clinical remission in pediatric severe asthma, emphasizing lung function as a key parameter for children.
View more
ADVENT On Air | Breathing Easy: Navigating Lung Function in <b>Pediatric</b> Severe Asthma With Spirometry and Beyond
Podcast

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

Pulmonology
Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.
View more
Why Is It Important to Assess Lung Function in <b>Pediatric</b> Asthma
interactivity

Why Is It Important to Assess Lung Function in Pediatric Asthma

Pulmonology
Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma
View more
Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers
expert video

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers

Dermatology
Explore the impact of moderate-to-severe atopic dermatitis on sleep in pediatric patients – a short soundbite from EADV 2022.
View more
High Burden of Atopic Dermatitis in Children
expert video

High Burden of Atopic Dermatitis in Children

Dermatology
Explore the debilitating effects that impact day-to-day functioning in pediatric patients with atopic dermatitis – a short soundbite from EADV 2022.
View more
Current systemic therapies have been shown to induce remission in a subset of AD patients
expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

Dermatology
Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.
View more
Most Children With Atopic Dermatitis Have Uncontrolled Disease
expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

Dermatology
Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.
View more
Association of Younger Age of Onset With Persistence of AD
expert video

Association of Younger Age of Onset With Persistence of AD

Dermatology
Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.
View more
Emerging Data on Advanced Systemic Treatments for Children With AD
expert video

Emerging Data on Advanced Systemic Treatments for Children With AD

Dermatology
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga reviewing the systemic treatment landscape for children under 12 years of age with AD in the EU. Dr. Baselga also discusses the latest clinical data on the use of baricitinib in pediatric patients aged 2 to 17 years, and both clinical and real-world data on the efficacy and safety of dupilumab in pediatric patients with AD aged as young as 6 months.
View more
KOL Video Interview – Dr. Eric Simpson
expert video

KOL Video Interview – Dr. Eric Simpson

Dermatology
In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.
View more
The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers
expert video

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers

Dermatology
Discover the multidimensional impact of pediatric atopic dermatitis on children and caregivers – a soundbite from the Expert Lounge Canada 2022.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region